Son Dönem Böbrek Yetersizlikli Hastalarda Prohepsidin ve Kardiyovasküler Risk Belirteçleri Arasındaki İlişki

1. Thijssen S, Usvyat L, Kotanko P: Prediction of mortality in the fi rst
two years of hemodialysis: Results from a validation study. Blood
Purif 2012; 33: 165-170
2. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu
M: Clinical value of the malnutrition–infl ammation–atherosclerosis
syndrome for long-term prediction of cardiovascular mortality in
patients with end-stage renal disease: A 5-year prospective study.
Nephron Clin Pract 2008; 108: 99-105
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy
D: Cardiovascular disease and mortality in a community-based
cohort with mild renal insuffi ciency. Kidney Int 1999; 56: 2214-
22194. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH:
Longitudinal follow-up and outcomes among a population with
chronic kidney disease in a large managed care organization. Arch
Intern Med 2004; 164: 659-663
5. Cohen LM, Ruthazer R, Moss AH, Germain MJ: Predicting sixmonth
mortality for patients who are on maintenance hemodialysis.
Clin J Am Soc Nephrol 2010; 5: 72-79
6. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot
P, Loréal O: A new mouse liver-specifi c gene, encoding a
protein homologous to human antimicrobial peptide hepcidin is
overexpressed during iron overload. J Biol Chem 2001; 276(11):
7811-7819
7. Vyoral D, Petrak J. Hepcidin: A direct link between iron metabolism
and immunity. Int J Biochem Cell Biol 2005; 37(9): 1768-1773
8. Détivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB,
Leroyer P, Ropert M, Jacquelinet S, Courselaud B, Ganz T, Brissot
P, Loréal O: Hepcidin levels in humans are correlated with hepatic
iron stores, hemoglobin levels, and hepatic function. Blood 2005;
106(2): 746-748
9. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary
antimicrobial peptide synthesized in the liver. J Biol Chemc 2001;
276: 7806-7810
10. Sullivan JL: Macrophage iron, hepcidin, and atherosclerotic plaque
stability. Exp Biol Med (Maywood) 2007; 232: 1014-1020
11. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C,
Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S: Severe
iron defi ciency anemia in transgenic mice expressing liver hepcidin.
Proc Natl Acad Sci USA 2002; 99(7): 4596-4601
12. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin
transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci
USA 2005; 102: 1906-1910
13. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D:
Time-course analysis of hepcidin, serum iron, and plasma cytokine
levels in humans injected with LPS. Blood 2005; 106: 1864-1866
14. Arabul M, Gullulu M, Yilmaz Y, Eren MA, Baran B, Gul CB,
Kocamaz G, Dilek K: Infl uence of erythropoietin therapy on serum
prohepcidin levels in dialysis patients. Med Sci Monit 2009; 15:
583-587
15. Atanasiu V, Manolescu B, Stoian I: Hepcidin the link between
infl ammation and anemia in chronic renal failure. Rom J Intern Med
2006; 44: 25-33
16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R,
Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger
I: Recommendations for quantifi cation of the left ventricle
by two-dimensional echocardiography. American Society of
Echocardiography Committee on Standards, Subcommittee on
Quantifi cation of Two-Dimensional Echocardiograms. J Am Soc
Echocardiogr 1989; 2: 358-367
17. Devereux RB, Reicheck N: Echocardiographic determination of
left ventricular mass in men: Anatomic validation of the method.
Circulation 1977; 55: 613-61818. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best
LG, Lee ET, Devereux RB; Strong Heart Study Investigators:
Normalization for body size and population-attributable risk of left
ventricular hypertrophy: The strong heart Study. Am J Hypertens
2005; 18: 191-196
19. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C,
Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L: Cystatin
C and infl ammatory markers in the ambulatory elderly. Am J Med
2005; 118: 1416-1431
20. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR:
Prohepcidin accumulates in renal insuffi ciency. Clin Chem Lab
Med 2004; 42: 387-389
21. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I,
Beaumont C, Kahn A, Vaulont S: The gene encoding the iron
regulatory peptide hepcidin is regulated by anemia, hypoxia, and
infl ammation. J Clin Invest 2002; 110(7): 1037-1044
22. Hsu SP, Chiang CK, Chien CT, Hung KY: Plasma prohepcidin
positively correlates with hematocrit in chronic hemodialysis
patients. Blood Purif 2006; 24: 311-31623. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot
P, Loréal O: A new mouse liver-specifi c gene, encoding a
protein homologous to human antimicrobial peptide hepcidin, is
overexpressed during iron overload. J Biol Chem 2001; 276: 7811-
7819
24. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson
A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the
prediction of death from cardiovascular causes. N Engl J Med 2008;
358: 2107-2116
25. Kannel WB: Left ventricular hypertrophy as a risk factor: The
Framingham experience. J Hypertens Suppl 1991; 9: 3-8
26. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G,
Cataliotti A, Seminara G, Stancanelli B, Malatino LS; CREED
Investigators: Prognostic impact of the indexation of left ventricular
mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12:
2768-2774